Global point of care molecular diagnostics market is anticipated to reach USD 3.9 billion by 2024,
according to a new report by Grand View Research, Inc. Ongoing research &
development to miniaturize molecular diagnostics testing that provides enhanced
near patient testing with high accuracy & lesser turnaround times are major
factors expected to reinforce the high growth potential for POC MDx products.
Growing demand for CLIA tests that are, by definition,
portable and safe enough to be used in non-laboratory settings such as pharmacy
clinics, physician offices, and home-care settings, is expected to drive demand
in the market over the forecast period. Ongoing research and development is
continually supported and funded by a number of major international entities
including the national governments of developed countries and high-value
private funding agencies such as the Bill & Melinda Gates Foundation.
Furthermore, a growing portfolio of point-of-care testing
capabilities that, had initially been focused on screening, testing, and
diagnosis of infectious diseases in low-income developing countries, has been
developing at a rapid pace over the past decade to expand its potential market
to a broader range of medical faculties. Consequently, POC and molecular
diagnosis tests are available and/or are under development for cardiology
monitoring, oncology testing, and hematology testing.
Recent advances in the development of microfluidics and
genetic sequencing instrumentation pave the way for development of
cost-effective, highly accurate and rapid testing platforms, which are able to
be used as true POC systems. This is a key factor that significantly contributes
towards the favorably funded, high growth potential environment prevalent in
the point of care molecular diagnostics market.
Browse full report by
Grand View Research :
Further key findings from the report suggest:
·
Application of POC MDx tests for infectious
diseases accounted for over 45% of market revenue in 2015. The large share can
be accounted for by the presence of an extensive portfolio of the concerned
tests with a number of major market entities. Furthermore, growing disease
burden of infectious diseases in developing as well as developed countries is
another factor the reinforces the dominance of this segment.
·
PCR-based POC tests accounted for the
largest share of the market in 2015. Widespread usage of PCR-based techniques
for molecular diagnosis and commercialization of POC real time PCR products
such as the cobas LIAT by Roche have provided this segment with ample
opportunities for revenue generation and are expected to maintain a favorable
market environment over the forecast period.
·
North America was observed to be the most
lucrative region on this market and estimated to account for over 40% of the
global revenue. presence of a technologically advanced medical framework,
sophisticated insurance & copayment system & high R&D investment by
governments and private funding organizations for the development of POC MDx tests
are major factors responsible for the region’s dominant market position.
·
Key players operating in this industry
include Johnson & Johnson, Danaher Corp., Cepheid, Bio-Rad Laboratories,
bioMerieux, Becton Dickinson, Roche Diagnostics, Bayer Healthcare, Alere Inc
(Abbott), Abbott Laboratories among others.
Browse more reports of
this category by Grand View Research: http://www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has
segmented point of care molecular diagnostics market on the basis of workflow,
mode, services, and region:
Global Point
of Care Molecular Diagnostics Application Outlook (Revenue, USD Million, 2013 -
2024)
·
Infectious Diseases
·
Oncology
·
Hematology
·
Prenatal Testing
·
Endocrinology
·
Other Applications
Global Point
of Care Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2013 -
2024)
·
PCR-based
·
Genetic Sequencing-based
·
Hybridization-based
·
Microarray-based
Global Point
of Care Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2013
- 2024)
·
OTC
·
POC
Global Point
of Care Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2013 -
2024)
·
Decentralized Labs
·
Hospitals
·
Home-care
·
Assisted Living Healthcare Facilities
·
Other uses
Point of
Care Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o
South Africa
View press
release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more
information: www.grandviewresearch.com
